40 results on '"Pecen L"'
Search Results
2. Persistence to edoxaban treatment in patients with atrial fibrillation: Analysis from the Global ETNA-AF program
3. Effect of perceived and objectively-assessed frailty on outcomes in edoxaban-treated patients with atrial fibrillation: data from the ETNA-AF-Europe 4-year follow-up
4. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
5. Two-year outcomes of patients with atrial fibrillation and heart failure: the ETNA-AF-Europe registry
6. Clinical outcomes in patients with atrial fibrillation with or without concomitant diabetes after two years of edoxaban treatment: ETNA-AF-Europe registry
7. Two-year effectiveness and safety outcomes in 27,333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme
8. The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure
9. Real-world effectiveness and safety of edoxaban in patients with and without a history of ischaemic stroke: results from the ETNA-AF programme
10. The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe
11. Perceived frailty and clinical outcomes in men and women with atrial fibrillation treated with edoxaban: insights from the 2-year follow-up of ETNA-AF-Europe
12. Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment
13. 177P Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)
14. Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program
15. Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry
16. Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program
17. Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF
18. Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program
19. Mismatch repair status predicts survival after adjuvant treatment in stage II colon cancer patients
20. P668Aspirin for primary prevention of cardiovascular disease
21. Dendritic cell-based immunotherapy (DCVAC/OvCa) with chemotherapy in patients with platinum-sensitive, relapsed, epithelial ovarian carcinoma: Survival analysis of a phase II, open-label, randomized, multicenter trial (study SOV02)
22. P3837Net clinical benefit of NOACs vs. VKAs in elderly patients with atrial fibrillation: a pooled analysis from the real-world PREFER in AF and PREFER in AF PROLONGATION registries
23. P4604Residual stroke risk of anticoagulated patients with atrial fibrillation: PREFER in AF European registry
24. P5153Net clinical benefit of oral anticoagulation in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF registry
25. P4900Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation in the PREFER in AF registry
26. Doctors' Failure in Observance of the COPD Management Guidelines: Case of the CZECH Republic
27. Cost-Effectiveness of 13-Valent Versus 10-Valent Pneumococcal Conjugate Vaccine Use in Croatia National Vaccination Program
28. Multicriteria Decision Analysis (MCDA) In HTA – Pilot Study in the Czech Republic
29. Modeled Outcomes and Overall Costs of the 13-Valent Pneumococcal Conjugate Vaccine in the Tunisian National Vaccination Program
30. Hypothalamo-Pituitary Dysfunction in Patients With Chronic Subdural Hematoma
31. Impaired microvascular reactivity and endothelial function in patients with Cushing’s syndrome: influence of arterial hypertension
32. Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder
33. Diurnal blood pressure variationin pheochromocytoma, primary aldosteronism and Cushing's syndrome
34. Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study
35. Qualitative and Quantitative Detection of Urinary Human Complement Factor H-Related Protein (BTA stat and BTA TRAK) and Fragments of Cytokeratins 8, 18 (UBC Rapid and UBC IRMA) as Markers for Transitional Cell Carcinoma of the Bladder
36. Endogenous Fibrinolysis in Patients with Lower Extremity Ischemia
37. PLASMA HOMOCYSTEINE LEVELS AND OTHER CARDIOVASCULAR RISK FACTORS IN ELDERLY HYPERTENSIVE PATIENTS
38. Plasma Endothelin Levels in Patients with Abdominal Aortic Aneurysms
39. P26 Plasma endothelin levels in patients with abdominal aortic aneurysms
40. The role of endogenous markers in patients with lower extremity ischemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.